Shares of UCB SA (OTCMKTS:UCBJY – Get Free Report) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $97.61 and traded as high as $98.95. UCB shares last traded at $98.79, with a volume of 9,578 shares changing hands.
UCB Stock Performance
The stock has a fifty day simple moving average of $97.61 and a two-hundred day simple moving average of $95.55. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Insider Buying Explained: What Investors Need to Know
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Why Invest in 5G? How to Invest in 5G Stocks
- Alphabet’s Officially In A Bear Market—Time To Buy?
- 3 Best Fintech Stocks for a Portfolio Boost
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
